Tiny antibodies hold big promise for cancer treatment, UK says

Using antibodies derived from alpacas, a University of Kentucky research team has developed a tool that could lead to new therapies to stop the growth of several types of cancer.

While cancer researchers have known that a protein called PRL-3 is linked to the growth of colon, breast, lung, skin and blood cancers, there is little understanding about how it works due to a lack of tools to study it effectively.

With unique alpaca antibodies known as nanobodies, the team led by UK Markey Cancer Center researcher Jessica Blackburn developed the first effective tool to specifically target PRL-3.

The discovery brings scientists one step closer to developing a drug that can stop the expression of PRL-3 and the growth of cancer, says Blackburn.

“The nanobodies are valuable new tools that can help researchers better understand how PRL-3 contributes to cancer progression,” said Blackburn, an associate professor in the UK College of Medicine‘s Department of Molecular and Cellular Biochemistry. “Ultimately, this discovery opens up new possibilities for developing better treatments to fight cancer and improve the lives of patients.”

The PRL-3 nanobodies, developed in collaboration with UK’s Protein Core, showed promising results in lab tests highlighted in the journal PLoS ONE.

Blackburn says that the nanobodies’ ability to locate PRL-3 within cancer cells will give researchers new insights into what other proteins or molecules it interacts with, which will add to the understanding of its function in cancer. Their ability to attach to PRL-3 could also have potential for therapeutic development.

“Nanobodies that target other proteins are already in clinical trials for a variety of human diseases, so it could be possible for a PRL-3 nanobody to be used as a drug to bind to PRL-3 and inhibit its activity,” Blackburn said.

Alpacas are one of the very few animals that produce nanobodies, which are 10 times smaller than regular antibodies. Their size gives them the potential to enter a cell in ways that a normal antibody cannot, offering a promising tool for understanding disease and drug development.

UK is just one of a handful of institutions currently producing alpaca nanobodies used for biomedical research.